Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778102 | 0.83 | ALDH1A1 (0.46) | ALDH1A1RAB9AMEN1KMT2ADYRK3 | |
| SCHEMBL984674 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9AMEN1KMT2ADYRK3 | |
| SCHEMBL986424 | 0.81 | GAA (0.51) | ALDH1A1MEN1KMT2ACDK9MAPT | |
| SCHEMBL986055 | 0.81 | ALDH1A1 (0.42) | ALDH1A1RAB9AMEN1KMT2ADYRK3 | |
| SCHEMBL987534 | 0.80 | NPBWR1 (0.61) | ALDH1A1RAB9AMEN1KMT2AABL1 | |
| SCHEMBL3586363 | 0.78 | PKM (0.42) | ALDH1A1MEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL5251968 | 0.77 | NPC1 (0.59) | ALDH1A1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL987958 | 0.77 | ALDH1A1 (0.41) | ALDH1A1RAB9AMEN1KMT2AHTT | |
| SCHEMBL3662505 | 0.77 | ALDH1A1 (0.46) | ALDH1A1RAB9AMEN1KMT2ADYRK3 | |
| SCHEMBL984422 | 0.76 | RAB9A (0.59) | ALDH1A1RAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604050-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-12-10 | — | — | US | disclosed |
| EP-2235014-B1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-10-09 | — | — | EP | disclosed |
| US-8299114-B2 | Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2012-10-30 | — | — | US | disclosed |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-04 | — | — | US | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 1091/4885RAB9A 752/4885MEN1 1673/4885 |
| US-20110009400-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | ALDH1A1 1325/4885RAB9A 2888/4885MEN1 2166/4885 |
| US-20120252837-A1 | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, HDAC1 | ALDH1A1 1325/4885RAB9A 2888/4885MEN1 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.